Article
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy.
Nature - 1 Mar 2023
Puig-Saus Cristina, Sennino Barbara, Peng Songming, Wang Clifford L, Pan Zheng, Yuen Benjamin, Purandare Bhamini, An Duo, Quach Boi B, Nguyen Diana, Xia Huiming, Jilani Sameeha, Shao Kevin, McHugh Claire, Greer John, Peabody Phillip, Nayak Saparya, Hoover Jonathan, Said Sara, Jacoby Kyle, Dalmas Olivier, Foy Susan P, Conroy Andrew, Yi Michael C, Shieh Christine, Lu William, Heeringa Katharine, Ma Yan, Chizari Shahab, Pilling Melissa J, Ting Marc, Tunuguntla Ramya, Sandoval Salemiz, Moot Robert, Hunter Theresa, Zhao Sidi, Saco Justin D, Perez-Garcilazo Ivan, Medina Egmidio, Vega-Crespo Agustin, Baselga-Carretero Ignacio, Abril-Rodriguez Gabriel, Cherry Grace, Wong Deborah J, Hundal Jasreet, Chmielowski Bartosz, Speiser Daniel E, Bethune Michael T, Bao Xiaoyan R, Gros Alena, Griffith Obi L, Griffith Malachi, Heath James R, Franzusoff Alex, Mandl Stefanie J, Ribas Antoni
Abstract excerpt
Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells1-14. The large HLA allele diversity and limiting clinical samples have restricted the study of the landscape of neoantigen-targeted T cell responses in patients over their treatment course. Here we applied recently developed technologies15-17 to capture...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.